Contact | Print version | PDF version | Send article | RSS feed

Antibody Engineering Company F-Star Buys Back Royalty Obligations

TVM Capital Joins Investor Syndicate

01 Apr 2008 - f-star announced that it has acquired future royalty obligations to New Century Pharmaceuticals (NCP) via a one-off payment.
 
Modular Antibody Technology was originally developed by Prof. Florian Rueker, one of f-star's founders, in collaboration with NCP, a U.S. biopharmaceutical company. After f-star's foundation, NCP became one of the Company's common shareholders and had rights to future royalty payments. In the course of the transaction, f-star has now bought back these royalty obligations and TVM Capital, a transatlantic venture capital firm based in Munich and Boston, acquired NCP's minority stake in f-star.
 
"We are very pleased that our technology is now essentially free of royalty obligations," Gottfried Himmler, CEO of f-star, commented on the transaction. "And we are delighted to have TVM Capital, one of the leading life science investors in Europe, joining f-star's strong international investor syndicate."